Transmedics Group (TMDX) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Transmedics Group (TMDX) do?
Transmedics Group Inc (TMDX) is a U.S.-listed company in Healthcare (Medical Devices). What it does: Manufactures portable organ perfusion systems that pump warm, oxygenated blood through donor organs during transit. Keeps donor organs warm and functioning during transport using portable perfusion machines and its own aviation fleet. It is worth $3.27B on the market and sold $727.32M over the last year.
- Market cap
- $3.27B
- P/E ratio
- 25.8×
- Annual sales
- $727.32M
- Sector
- Healthcare
- Industry
- Medical Devices
- Brief updated
- Nov 17, 2026
Brands and businesses behind TMDX
- Organ Care System: Sells warm perfusion machines and single-use perfusion sets used to preserve donor hearts, lungs, and livers.
- National OCS Program: Provides turnkey organ retrieval logistics and clinical management services to transplant hospitals for a per-mission fee.
TMDX’s flags, in plain English
Each flag is a number from Transmedics Group’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 17, 2026.
Stupid Cash
Can pay this year's bills 4.5 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Still Climbing
Sales up 88.2% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.
Wide Gross Margin
Gross margin of 57.1% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Profit with Caveats
Bottom-line profit of $144M in the 12 months to Sep 30, 2026, next to $86M of profit from the business. Bottom-line profit is well above what the business itself earned. The difference came from outside day-to-day operations, such as an investment gain, a tax benefit, the sale of a business or interest on its cash. Some of these may not repeat, and they make the P/E look lower than the business alone would.
1 more green flag and 2 more risk notes open with the free trial. Try it free for 7 days.
Questions about TMDX
How big is Transmedics Group?
Transmedics Group’s market cap is $3.27B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $727.32M: what customers paid the company over the last year, before any costs.
What is TMDX’s P/E ratio?
TMDX’s P/E ratio is 25.8×. Investors pay about 25.8 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with TMDX?
The company relies on a single proprietary hardware platform across all three of its approved organ transplant markets. That is one risk on Transmedics Group’s card. Its first risk flag is Profit with Caveats, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Transmedics Group’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. TMDX’s filings on SEC.gov. The Margin Monkey is research, not advice.
